Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice.

Liangpeng Li,Hong Liu,Jiahe Peng,Yongchao Wang,Yan Zhang,Jinyu Dong,Xiaohua Liu,Dongmei Guo,Yu Jiang

DOI: https://doi.org/10.1016/j.bbrc.2013.10.156

IF: 3.1

2013-01-01

Biochemical and Biophysical Research Communications

Abstract:•FXR up-regulates apoF.•It binds to ER1 element.•It activates apoF gene promoter.

What problem does this paper attempt to address?

Farnesoid X receptor upregulates apolipoprotein F expression in cultured liver cells

Li Liangpeng,Liu Hong,Peng Jiahe,Wang Yongchao,Zhang Yan,Dong Jinyu,Jiang Yu

DOI: https://doi.org/10.16016/j.1000-5404.2011.09.009

2011-01-01

Abstract:Objective To determine the effect of farnesoid X receptor(FXR) on the expression of apolipoprotein F(ApoF) in human hepatoblastoma HepG2 cells and hepatocyte L02 cells.Methods After HepG2 cells and L02 cells were treated with FXR agonist chenodesoxycholic acid(CDCA) at 0,25,50 or 100 μmol/L,or with another agonist GW4064 at 0,0.02,0.2,or 2 μmol/L respectively,the mRNA expressions of FXR specific target gene small heterodimer partner(SHP) and ApoF were detected by reverse transcription polymerase chain reaction(RT-PCR).The apolipoprotein F protein level was determined by Western blotting.Results After treated with CDCA for 24 h,the mRNA levels of SHP and ApoF in the treated cells were significantly higher than the untreated cells(P<0.05),so did the protein expression of ApoF(0.884±0.091 vs 0.185±0.030,P<0.05).After treated with GW4064 for 24 h,the SHP and ApoF expressions at mRNA level were significantly increased in the treated cells than the untreated cells(P<0.05),so did the protein expression of ApoF(P<0.05).Conclusion After the treatment of CDCA and GW4064,FXR is activated in HepG2 cells and L02 cells,which upregulates the expression of apoF.
Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase

Li-Li Shen,Hong Liu,Jiahe Peng,Lin Gan,Li Lu,Qian Zhang,Liangpeng Li,Fengtian He,Yu Jiang

DOI: https://doi.org/10.1007/s11033-010-0140-0

Abstract:The farnesoid X receptor (FXR) is a nuclear receptor that regulates gene expression in response to bile acids (BAs). FXR plays an important role in the homeostasis of bile acid, cholesterol, lipoprotein and triglyceride. In this report, we identified fatty acid synthase (FAS) and hepatic lipase (HL) genes as novel target genes of FXR. Human hepatoma HepG2 cells were treated with chenodeoxycholic acid, the natural FXR ligand, and the messenger RNA and protein levels of FAS and HL were determined by RT-PCR and Western blot analysis, respectively. Chenodeoxycholic acid (CDCA) down-regulated the expression of FAS and HL genes in a dose and time-dependent manner in human hepatoma HepG2 cells. In addition, treatment of mice with CDCA significantly decreased the expression of FAS and HL in mouse liver and the activity of HL. These results demonstrated that FAS and HL might be FXR-regulated genes in liver cells. In view of the role of FAS and HL in lipogenesis and plasma lipoprotein metabolism, our results further support the central role of FXR in the homeostasis of fatty acid and lipid.
Farnesoid X receptor represses hepatic lipase gene expression

Audrey Sirvent,Adrie J M Verhoeven,Hans Jansen,Vladimir Kosykh,Raphaël J Darteil,Dean W Hum,Jean-Charles Fruchart,Bart Staels

DOI: https://doi.org/10.1194/jlr.M400221-JLR200

Abstract:The farnesoid X receptor (FXR) is a nuclear receptor that regulates gene expression in response to bile acids (BAs). FXR plays a central role in BA, cholesterol, and lipoprotein metabolism. Here, we identify HL, an enzyme involved in the metabolism of remnant and high density lipoproteins, as a novel FXR-regulated gene. The natural FXR ligand, chenodeoxycholic acid (CDCA), downregulates HL gene expression in a dose- and time-dependent manner in human hepatoma HepG2 cells. The nonsteroidal synthetic FXR agonist GW4064 also decreases HL mRNA levels in HepG2 cells and in primary human hepatocytes. Moreover, the decrease of HL mRNA levels after treatment with FXR agonists was associated with a significant decrease in secreted enzymatic activity. In addition, FXR-specific gene silencing using small interfering RNAs demonstrated that CDCA- and GW4064-mediated downregulation of HL transcript levels occurs via an FXR-dependent mechanism. Finally, using transient transfection experiments, it is shown that FXR represses transcriptional activity of a reporter driven by the -698/+13 bp human HL promoter. Taken together, these results identify HL as a new FXR-regulated gene in human liver cells. In view of the role of HL in plasma lipoprotein metabolism, our results further emphasize the central role of FXR in lipid homeostasis.
Farnesoid X receptor down-regulates expression of liver fatty acid-binding protein in liver cells

Dong Jinyu,Liu Hong,Peng Jiahe,Zhang Yan,Wang Qiang,Li Liangpeng,Wang Yongchao,Jiang Yu

DOI: https://doi.org/10.16016/j.1000-5404.2010.05.008

2010-01-01

Abstract:Objectives To investigate the effect of farnesoid X receptor(FXR) on the expression of liver fatty acid-binding protein(L-FABP) .Methods Human hepatoblastoma HepG2 cells and hepatocyte LO2 cells were treated with FXR agonists chenodesoxycholic acid(CDCA) at 50 and 100μmol/L or GW4064 at 1 and 5μmol/L respectively.The L-FABP and the specific gene of FXR-small heterodimer partner(SHP) were detected by reverse transcription polymerase chain reaction(RT-PCR) .The L-FABP protein level was determined by Western blotting.Results After treated with CDCA or GW4064,SHP mRNA level in HepG2 and LO2 was increased obviously,which suggested FXR was functional in those cells.The mRNA and protein levels of L-FABP was decreased dramatically in those cells(P<0.05) .Conclusion Farnesoid X receptor downregulates the expression of L-FABP in hepatocytes.
Role of fenofibrate in activation of farnesoid X receptor transcriptional activity

E WANG,Xuelian XIONG,Xiaolin WANG,Yan LU,Xiaoying LI

DOI: https://doi.org/10.3969/j.issn.1671-2870.2014.02.008

2014-01-01

Abstract:Objective: To investigate the mechanism of fenofibrate in regulating farnesoid X receptor (FXR) transcriptional activity. Methods:Mouse primary hepatocytes (MPH) were cultured and treated with fenofibrate or vehicle as control. Cells were harvested for RNA isolation and real-time PCR was performed to analyze expression levels of FXR down-stream gene, including SHP, BSEP and SREBP1c. Besides, transcriptional activity of FXR was determined by reporter luciferase assays. Results: Fenofibrate up-regulated mRNA levels of SHP and BSEP, and down-regulated expression of SREBP1c. Fenofibrate could transactivate promoter activity of SHP and BSEP in the presence of full-length FXR, but not the one with ligand-binding-domain or transactivation domain-2 deletion. Conclusions: Fenofibrate might be a potential agonist of FXR,and it could inhibit hepatic triglyceride accumulation by activating FXR signalling and down-regulating lipogenic genes.
Farnesoid X Receptor Activation Increases Cholesteryl Ester Transfer Protein Expression in Humans and Transgenic Mice

T. Gautier,W. de Haan,D. Ye,M. J. Bahr,T. Claudel,T. J. C. Van Berkel,J. Grober,L. Lagrost,F. Kuipers,M. Van Eck,P. C. N. Rensen,U. J. F. Tietge

DOI: https://doi.org/10.1194/jlr.m038141

IF: 6.676

2013-01-01

Journal of Lipid Research

Abstract:Cholesteryl ester transfer protein (CETP) activity results in a proatherogenic lipoprotein profile. In cholestatic conditions, farnesoid X receptor (FXR) signaling by bile acids (BA) is activated and plasma HDL cholesterol (HDL-C) levels are low. This study tested the hypothesis that FXR-mediated induction of CETP contributes to this phenotype. Patients with cholestasis and high plasma BA had lower HDL-C levels and higher plasma CETP activity and mass compared with matched controls with low plasma BA (each P < 0.01). BA feeding in APOE3*Leiden transgenic mice expressing the human CETP transgene controlled by its endogenous promoter increased cholesterol within apoB-containing lipoproteins and decreased HDL-C (each P < 0.01), while hepatic CETP mRNA expression and plasma CETP activity and mass increased (each P < 0.01). In vitro studies confirmed that FXR agonists substantially augmented CETP mRNA expression in hepatocytes and macrophages dependent on functional FXR expression (each P < 0.001). These transcriptional effects are likely mediated by an ER8 FXR response element (FXRE) in the first intron. In conclusion, using a translational approach, this study identifies CETP as novel FXR target gene. By increasing CETP expression, FXR activation leads to a proatherogenic lipoprotein profile. These results have clinical relevance, especially when considering FXR agonists as emerging treatment strategy for metabolic disease and atherosclerosis.
Role of Farnesoid X Receptor in Regulating Lipid Metabolism

SHEN Li-li,PENG Yan-meng,JIANG Yu

DOI: https://doi.org/10.3969/j.issn.1673-6273.2007.09.051

2007-01-01

Abstract:The farnesoid X receptor(FXR)belongs to the ligand-activated nudear receptor transcription factors.It can be activated by endogenic ligand bile-acid.FXR is essential in maintaining homeostasis and metabolism of serum lipids by regulating bile-acid,cholesterol,lipoprotein,and fatty acid.Recently,FXR has been found active in vasculature,which is a new direction in research of regulation of lipid homeostasis by FXR.With the development of its new ligand and target gene,it is meaningful to in- vestigate the mechanism of FXR and find the ligand of FXR in lipid homeostasis.This experiment is important for the study of abnormal metabolism of lipids and the prevention of atherosclerosis.Here the latest advancement in this field is reviewed in this pa- per.
Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

Xinzhu Liu,Jiaxuan Wang,Maogang Li,Jiannan Qiu,Xingying Li,Li Qi,Jia Liu,Ping Liu,Guoxiang Xie,Xiaoning Wang

DOI: https://doi.org/10.1111/jgh.16279

2023-07-07

Journal of Gastroenterology and Hepatology

Abstract:Background and Aim The prevalence of nonalcoholic fatty liver disease (NAFLD) has been rising globally. NAFLD patients combined with cholestasis have more obvious liver fibrosis, impaired bile acid (BA), and fatty acid (FA) metabolism and severer liver injury; however, its therapeutic options are limited, and the underlying metabolic mechanisms are understood. Here, we aimed to investigate the effects of farnesoid X receptor (FXR) on BA and FA metabolism in NAFLD combined with cholestasis and related signaling pathways. Methods A mouse model of NAFLD combined with cholestasis was established by joint intervention with high‐fat diet (HFD) and alpha‐naphthylisothiocyanate. The effects of FXR on BA and FA metabolism were evaluated by serum biochemical analysis. Liver damage was identified by histopathology. The expression of nuclear hormone receptor, membrane receptor, FA transmembrane transporter, and BA transporter protein in mice were measured by western blot. Results NAFLD mice combined with cholestasis developed more severe cholestasis and dysregulated BA and FA metabolism. Meanwhile, the expression of FXR protein was decreased in NAFLD mice combined with cholestasis compared to the controls. Fxr−/− mice showed liver injury. HFD aggravated the liver injury with decreased BSEP expression, increased expression of NTCP, LXRα, SREBP‐1c, FAS, ACC1, and CD36, and significantly increased BA and FA accumulation. Conclusion All the results suggested that FXR plays a key role in both FA and BA metabolism in NAFLD combined with cholestasis and thus may be a potential target for the treatment of disorders of BA and FA metabolism in NAFLD combined with cholestasis.

gastroenterology & hepatology
Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells

FengtianHe,Jiang-Li,Ying Mu,RamalingaKuruba,ZhengMa,AnnetteWilson,SeanAlber,YuJiang,TroyStevens,SimonWatkins,BrucePitt,Wen-Xie,SongLi

IF: 23.213

2006-01-01

Circulation Research

Abstract:The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that is highly expressed in liver, kidney, adrenals, and intestine. FXR may play an important role in the pathogenesis of cardiovascular diseases via regulating the metabolism and transport of cholesterol. In this study, we report that FXR is also expressed in rat pulmonary artery endothelial cells (EC), a “nonclassical” bile acid target tissue. FXR is functional in EC, as demonstrated by induction of its target genes such as small heterodimer partner (SHP) after treatment with chenodeoxycholic acid, a FXR agonist. Interestingly, activation of FXR in EC led to downregulation of endothelin (ET)-1 expression. Reporter assays showed that activation of FXR inhibited transcriptional activation of the human ET-1 gene promoter and also repressed the activity of a heterologous promoter driven by activator protein (AP)-1 response elements. Electrophoretic mobility-shift and chromatin immunoprecipitation assays indicated that FXR reduced...
FXR Antagonist FLG249 Lowers Hepatic Triacylglycerol and Serum Cholesterol Level in High-Fat Diet-Induced Obese Mice

Yusuke Iguchi,Yukiko Yamashita,Keigo Gohda,Keisuke Oda,Ko Fujimori,Yukihiro Sera,Tsuneo Imanaka,Masafumi Yamaguchi,Mizuho Une,Naoki Teno

DOI: https://doi.org/10.1248/bpb.b24-00311

Abstract:Farnesoid X receptor (FXR) is a nuclear receptor that regulates the synthesis and enterohepatic circulation of bile acids (BAs). It also regulates lipid and carbohydrate metabolism, making FXR ligands potential therapeutic agents for systemic and/or hepatic metabolic disorders. We previously synthesized a series of FXR antagonists and showed that oral administration of FLG249 reduced the expression of several FXR target genes in the mouse ileum. Here, we investigated the effects of FLG249 on lipid metabolism in mice fed a high-fat diet (HFD). When FLG249 was administered for 4 weeks to HFD-induced obese mice, it altered the expression of genes related to BA metabolism, ceramide synthesis and fatty acid β-oxidation, improving lipid metabolism in the liver and ileum without decreasing body weight. These findings suggest that FLG249 has the potential to be a low toxicity pharmaceutical compound and likely acts as a nonsteroidal FXR antagonist to improve lipid metabolism disorders.
Farnesoid X Receptor： a Master Regulator of Hepatic Triglyceride and Glucose Homeostasis

Yang Jiao,Yan Lu,Xiao-ying Li

DOI: https://doi.org/10.1038/aps.2014.116

IF: 7.169

2015-01-01

Acta Pharmacologica Sinica

Abstract:Non-alcoholic fatty liver disease （NAFLD） is characterized by the aberrant accumulation of triglycerides in hepatocytes in the absence of significant alcohol consumption, viral infection or other specific causes of liver disease. NAFLD has become a burgeoning health problem both worldwide and in China, but its pathogenesis remains poorly understood. Farnesoid X receptor （FXR）, a member of the nuclear receptor （NR） superfamily, has been demonstrated to be the primary sensor for endogenous bile acids, and play a crucial role in hepatic triglyceride homeostasis. Deciphering the synergistic contributions of FXR to triglyceride metabolism is critical for discovering therapeutic agents in the treatment of NAFLD and hypertriglyceridemia.
Farnesoid X Receptor (FXR): Structures and Ligands.

Longying Jiang,Huajun Zhang,Desheng Xiao,Hudie Wei,Yongheng Chen

DOI: https://doi.org/10.1016/j.csbj.2021.04.029

IF: 6.155

2021-01-01

Computational and Structural Biotechnology Journal

Abstract:Farnesoid X receptor (FXR) is a bile acid activated nuclear receptor (BAR) and is mainly expressed in the liver and intestine. Upon ligand binding, FXR regulates key genes involved in the metabolic process of bile acid synthesis, transport and reabsorption and is also involved in the metabolism of carbohydrates and lipids. Because of its important functions, FXR is considered as a promising drug target for the therapy of bile acid-related liver diseases. With the approval of obeticholic acid (OCA) as the first small molecule to target FXR, many other small molecules are being evaluated in clinical trials. This review summarizes the structures of FXR, especially its ligand binding domain, and the development of small molecules (including agonists and antagonists) targeting FXR.
Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver

Bing Wang,Haibo Zhang,Zhilin Luan,Hu Xu,Yuanyi Wei,Xuejia Zhao,Miaomiao Xing,Xiaoxiao Huo,Jiayang Zhang,Wen Su,Youfei Guan,Xiaoyan Zhang

DOI: https://doi.org/10.1016/j.yexcr.2020.111949

2020-05-01

Abstract:Farnesoid X receptor (FXR) is a metabolic nuclear receptor, which protects liver from many endogenous and exogenous injuries. Metallothioneins (MTs) belong to a low-molecular-weight protein family involved in metal homeostasis and the regulation of hepatic oxidative stress. In the present study, we aimed to investigate the effect of FXR on hepatic MT1 expression and the underlying mechanism. C57BL/6 mice or primary cultured mouse hepatocytes were treated with the synthetic FXR ligand GW4064 or natural ligand CDCA. RNA-Sequencing (RNA-seq) analysis was performed to identify gene expression profile in the livers of mice treated with GW4064. Real-time PCR and Western blot were applied to determine the expression of MT1 and other FXR target genes in the livers of mice and primary hepatocytes treated with GW4064 and CDCA. Cellular and subcellular locations of MT1 in the livers of mice treated with GW4064 were examined using immunohistochemistry assay. FXR small interfering RNAs (siRNA) was transfected to silence FXR. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were utilized to confirm the regulation of MT1 gene promoter activity by FXR. RNA-seq analysis revealed that GW4064 treatment significantly induced MT1 expression in mouse liver. Consistently, MT1 expression in the hepatocytes of mouse livers and cultured hepatocytes was upregulated by GW4064 as well as CDCA. In addition, adenovirus-mediated overexpression of FXR markedly increased, while siRNA-mediated FXR silencing significantly suppressed MT1 expression in cultured hepatocytes. Luciferase reporter and ChIP assays further confirmed that the MT1 gene was under the direct control of FXR. Collectively, our findings demonstrate that MT1 is a novel target gene of FXR and may contribute to antioxidative capacity of FXR in liver diseases.
Effects of Farnesoid X Receptor on the Expression of Hepatic Lipase

SHEN Li-li,PENG Jia-he,GAN Lin,LU Li,ZHANG Qian,JIANG Yu

DOI: https://doi.org/10.3969/j.issn.1673-6273.2007.11.017

2007-01-01

Abstract:Objective:To investigate the effect of the famesoid X receptor on hepatic lipase expression.Methods:Human hepato- blastoma HepG2 cells were treated with chenodeoxycholic acid and the levels of HL messenger RNA and protein were determined by RT-PCR and Western blotting respectively.Results:HepG2 cells were treated with FXR agonists CDCA with different concentrations of 25μmol/L,50μmol/L,75μmol/L for 6h,12h,24h and 48h,and the levels of HL mRNA and protein were decreased in a dose and time-de- pendent manner.Conclusions:FXR agonist decreases hepatic lipase gene expression.
Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice

Eva Hambruch,Shinobu Miyazaki-Anzai,Ulrike Hahn,Silke Matysik,Alfred Boettcher,Sanja Perović-Ottstadt,Thomas Schlüter,Olaf Kinzel,Helen Desiree Krol,Ulrich Deuschle,Michael Burnet,Moshe Levi,Gerd Schmitz,Makoto Miyazaki,Claus Kremoser

DOI: https://doi.org/10.1124/jpet.112.196519

Abstract:Farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor, plays an important role in the regulation of cholesterol and more specifically high-density lipoprotein (HDL) homeostasis. Activation of FXR is reported to lead to both pro- and anti-atherosclerotic effects. In the present study we analyzed the impact of different FXR agonists on cholesterol homeostasis, plasma lipoprotein profiles, and transhepatic cholesterol efflux in C57BL/6J mice and cynomolgus monkeys and atherosclerosis development in cholesteryl ester transfer protein transgenic (CETPtg) low-density lipoprotein receptor (LDLR) (-/-) mice. In C57BL/6J mice on a high-fat diet the synthetic FXR agonists isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate (FXR-450) and 4-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]phenyl]cyclopropyl]benzoic acid (PX20606) demonstrated potent plasma cholesterol-lowering activity that affected all lipoprotein species, whereas 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064) and 6-ethyl chenodeoxycholic acid (6-ECDCA) showed only limited effects. In FXR wild-type mice, but not FXR(-/-) mice, the more efficacious FXR agonists increased fecal cholesterol excretion and reduced intestinal cholesterol (re)uptake. In CETPtg-LDLR(-/-) mice PX20606 potently lowered total cholesterol and, despite the observed HDL cholesterol (HDLc) reduction, caused a highly significant decrease in atherosclerotic plaque size. In normolipidemic cynomolgus monkeys PX20606 and 6-ECDCA both reduced total cholesterol, and PX20606 specifically lowered HDL(2c) but not HDL(3c) or apolipoprotein A1. That pharmacological FXR activation specifically affects this cholesterol-rich HDL(2) subclass is a new and highly interesting finding and sheds new light on FXR-dependent HDLc lowering, which has been perceived as a major limitation for the clinical development of FXR agonists.
Noncanonical Farnesoid X Receptor Signaling Inhibits Apoptosis and Impedes Liver Fibrosis

Hong Wang,Chaoliang Ge,Jiyu Zhou,Yitong Guo,Shuang Cui,Ningning Huang,Tingting Yan,Lijuan Cao,Yuan Che,Qiuling Zheng,Xiao Zheng,Frank J. Gonzalez,Guangji Wang,Haiping Hao

DOI: https://doi.org/10.1016/j.ebiom.2018.10.028

IF: 11.205

2018-01-01

EBioMedicine

Abstract:•FXR physically interacts with CASP8 in cytoplasm.•FXR inhibits death receptors-engaged apoptosis independent of transactivation.•Reduction of cytosolic FXR is a prerequisite initiating apoptosis cascade.•Forced overexpression of FXR impedes liver fibrosis.
Mechanism of tissue‐specific farnesoid X receptor in suppressing the expression of genes in bile‐acid synthesis in mice

John Y.L. Chiang,Grace L. Guo,Curtis D. Klaassen,Youcai Zhang,Bo Kong,Li Wang

DOI: https://doi.org/10.1002/hep.25740

IF: 17.298

2012-09-01

Hepatology

Abstract:Activation of farnesoid X receptor (Fxr, Nr1h4) is a major mechanism in suppressing bile‐acid synthesis by reducing the expression levels of genes encoding key bile‐acid synthetic enzymes (e.g., cytochrome P450 [CYP]7A1/Cyp7a1 and CYP8B1/Cyp8b1). FXR‐mediated induction of hepatic small heterodimer partner (SHP/Shp, Nr0b2) and intestinal fibroblast growth factor 15 (Fgf15; FGF19 in humans) has been shown to be responsible for this suppression. However, the exact contribution of Shp/Fgf15 to this suppression, and the associated cell‐signaling pathway, is unclear. By using novel genetically modified mice, the current study showed that the intestinal Fxr/Fgf15 pathway was critical for suppressing both Cyp7a1 and Cyp8b1 gene expression, but the liver Fxr/Shp pathway was important for suppressing Cyp8b1 gene expression and had a minor role in suppressing Cyp7a1 gene expression. Furthermore, in vivo administration of Fgf15 protein to mice led to a strong activation of extracellular signal‐related kinase (ERK) and, to a smaller degree, Jun N‐terminal kinase (JNK) in the liver. In addition, deficiency of either the ERK or JNK pathway in mouse livers reduced the basal, but not the Fgf15‐mediated, suppression of Cyp7a1 and Cyp8b1 gene expression. However, deficiency of both ERK and JNK pathways prevented Fgf15‐mediated suppression of Cyp7a1 and Cyp8b1 gene expression. Conclusion: The current study clearly elucidates the underlying molecular mechanism of hepatic versus intestinal Fxr in regulating the expression of genes critical for bile‐acid synthesis and hydrophobicity in the liver. (HEPATOLOGY 2012;56:1034–1043)

Medicine,Biology
Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4

Wenyi Deng,Wenjing Fan,Tingting Tang,Hengquan Wan,Simin Zhao,Yao Tan,Kwabena Agyare Oware,Jieqiong Tan,Jiequn Li,Shunlin Qu

DOI: https://doi.org/10.1155/2022/3589525

2022-02-24

Oxidative Medicine and Cellular Longevity

Abstract:Farnesoid X receptors (FXR) are bile acid receptors that play roles in lipid, glucose, and energy homeostasis. Synthetic FXR-specific agonists have been developed for treating nonalcoholic fatty liver disease (NAFLD) patients. However, the detailed mechanism remains unclear. To investigate the effects of FXR on NAFLD and the possible mechanism, FXR-null mice were fed either a normal or a high-fat diet. The FXR-null mice developed hepatomegaly, steatosis, accumulation of lipid droplets in liver cells, glucose metabolism disorder, and elevated serum lipid levels. Transcriptomic results showed increased expression of key lipid synthesis and glucose metabolism-related proteins. We focused on pyruvate dehydrogenase kinase 4 (PDK4), a key enzyme involved in the regulation of glucose and fatty acid (FA) metabolism and homeostasis. Subsequently, we confirmed an increase in PDK4 expression in FXR knockout cells. Moreover, inhibition of PDK4 expression alleviated lipid accumulation in hepatocytes caused by FXR deficiency in vivo and in vitro. Our results identify FXR as a nuclear transcription factor that regulates glucose and lipid metabolism balance through PDK4, providing further insights into the mechanism of FXR agonists in the treatment of metabolic diseases.

cell biology
Activation of farnesoid X receptor induces RECK expression in mouse liver.

Xiaomin Peng,Weibin Wu,Bo Zhu,Zhichao Sun,Lingling Ji,Yuanyuan Ruan,Meiling Zhou,Lei Zhou,Jianxin Gu

DOI: https://doi.org/10.1016/j.bbrc.2013.11.082

IF: 3.1

2013-01-01

Biochemical and Biophysical Research Communications

Abstract:Farnesoid X receptor (FXR) belongs to the ligand-activated nuclear receptor superfamily, and functions as a transcription factor regulating the transcription of numerous genes involved in bile acid homeostasis, lipoprotein and glucose metabolism. In the present study, we identified RECK, a membrane-anchored inhibitor of matrix metalloproteinases, as a novel target gene of FXR in mouse liver. We found that FXR agonist substantially augmented hepatic RECK mRNA and protein expression in vivo and in vitro. FXR regulated the transcription of RECK through directly binding to FXR response element located within intron 1 of the mouse RECK gene. Moreover, FXR agonist reversed the down-regulation of RECK in the livers from mice fed a methionine and choline deficient diet. In summary, our data suggest that RECK is a novel transcriptional target of FXR in mouse liver, and provide clues to better understanding the function of FXR in liver.
Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis

Juliane Tschuck,Lea Theilacker,Ina Rothenaigner,Stefanie A. I. Weiß,Banu Akdogan,Van Thanh Lam,Constanze Müller,Roman Graf,Stefanie Brandner,Christian Pütz,Tamara Rieder,Philippe Schmitt-Kopplin,Michelle Vincendeau,Hans Zischka,Kenji Schorpp,Kamyar Hadian

DOI: https://doi.org/10.1038/s41467-023-42702-8

IF: 16.6

2023-10-30

Nature Communications

Abstract:Abstract Ferroptosis is a regulated cell death modality that occurs upon iron-dependent lipid peroxidation. Recent research has identified many regulators that induce or inhibit ferroptosis; yet, many regulatory processes and networks remain to be elucidated. In this study, we performed a chemical genetics screen using small molecules with known mode of action and identified two agonists of the nuclear receptor Farnesoid X Receptor (FXR) that suppress ferroptosis, but not apoptosis or necroptosis. We demonstrate that in liver cells with high FXR levels, knockout or inhibition of FXR sensitized cells to ferroptotic cell death, whereas activation of FXR by bile acids inhibited ferroptosis. Furthermore, FXR inhibited ferroptosis in ex vivo mouse hepatocytes and human hepatocytes differentiated from induced pluripotent stem cells. Activation of FXR significantly reduced lipid peroxidation by upregulating the ferroptosis gatekeepers GPX4, FSP1, PPARα, SCD1, and ACSL3. Together, we report that FXR coordinates the expression of ferroptosis-inhibitory regulators to reduce lipid peroxidation, thereby acting as a guardian of ferroptosis.

multidisciplinary sciences

Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice.

Farnesoid X receptor upregulates apolipoprotein F expression in cultured liver cells

Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase

Farnesoid X receptor represses hepatic lipase gene expression

Farnesoid X receptor down-regulates expression of liver fatty acid-binding protein in liver cells

Role of fenofibrate in activation of farnesoid X receptor transcriptional activity

Farnesoid X Receptor Activation Increases Cholesteryl Ester Transfer Protein Expression in Humans and Transgenic Mice

Role of Farnesoid X Receptor in Regulating Lipid Metabolism

Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells

FXR Antagonist FLG249 Lowers Hepatic Triacylglycerol and Serum Cholesterol Level in High-Fat Diet-Induced Obese Mice

Farnesoid X Receptor： a Master Regulator of Hepatic Triglyceride and Glucose Homeostasis

Farnesoid X Receptor (FXR): Structures and Ligands.

Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver

Effects of Farnesoid X Receptor on the Expression of Hepatic Lipase

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice

Noncanonical Farnesoid X Receptor Signaling Inhibits Apoptosis and Impedes Liver Fibrosis

Mechanism of tissue‐specific farnesoid X receptor in suppressing the expression of genes in bile‐acid synthesis in mice

Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4

Activation of farnesoid X receptor induces RECK expression in mouse liver.

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis